You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Fig. 4

Reduction in TIL eTreg cells after RAM-containing therapies. a Kinetic changes of CD4+ T cells, CD8+ T cells, and eTreg cells. The frequency of eTreg cells in TILs significantly decreased following RAM-containing therapies (22.67 ± 11.19% vs. 16.33 ± 8.44%; P = 0.034), while no significant difference was observed in eTreg cells in PBMCs (1.97 ± 1.15% vs. 1.89 ± 0.85%; P = 0.74). There was no significant difference in the frequency of CD4+ T cells and CD8+ T cells between pre- and post-treatment. The averages were used if more than one samples at post-treatment were available. n.s., not significant. b % of changes from base line of CD4+ T cells, CD8+ T cells, and eTreg cells. The kinetic changes are more dynamic in TILs compared with PBMCs especially in CD4+ T cells and CD8+ T cells. eTreg cells showed a trend to decrease in TIL. c IHC for CD4, FOXP3 and Ki67. FOXP3+CD4+ T cells and Ki67+FOXP3+CD4+ T cells were reduced after RAM monotherapy. Blue, DAPI; green, CD4 (upper) or Ki67 (lower); red, FOXP3

Back to article page